Logo 400x400.jpg
CytoSorbents Highlights Upcoming Presentations at EACTS 2023: Focus on Antithrombotic Removal including the 2nd Analysis of the International STAR Registry
September 27, 2023 07:00 ET | CytoSorbents
CytoSorbents summarizes real-world data from STAR Registry analysis being presented next week at European Association of Cardio-Thoracic Surgery Congress
1ST Biotherapeutics Announces Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate FB849 in Combination With KEYTRUDA® (pembrolizumab)
September 19, 2023 04:00 ET | AKAMPION
YONGIN, South Korea, September 19, 2023 -- 1ST Biotherapeutics, Inc., a clinical-stage biotechnology company focused on the development of novel small molecule therapeutics in neurodegenerative...
adrenomed-logo (002).jpg
Adrenomed presents new findings on its precision medicine treatment for septic shock with enibarcimab during Weimar Sepsis Update
September 08, 2023 04:00 ET | Adrenomed AG
Patient population benefitting most from enibarcimab treatment in septic shock can clearly be defined by two biomarkers, as shown by data presented todayIn the AdrenOSS-2 trial, the respective patient...
logo.png
Jupiter Wellness Reports Positive Efficacy Results from Clinical Study for its NoStingz Topical Jellyfish Protection Sunscreen
August 09, 2023 08:45 ET | Jupiter Wellness, Inc
Data show NoStingz proprietary formulation provides protection against jellyfish stings including Portuguese man-o’-war JUPITER, FL, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Jupiter Wellness, Inc....
Groundbreaking Study
Groundbreaking Study in Nature Digital Medicine Establishes Sword Health’s Digital Physical Therapy Program as the New Gold Standard of Care for the 50 Million Americans Who Endure Physical Pain Daily
July 10, 2023 09:00 ET | SWORD Health
NEW YORK, July 10, 2023 (GLOBE NEWSWIRE) -- Today, Sword Health, the world’s first end-to-end platform to predict, prevent and treat pain, is announcing its digital physical therapy program has been...
revive-therapeutics.png
Revive Therapeutics Announces Results of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
July 06, 2023 06:30 ET | Revive Therapeutics Ltd.
TORONTO, July 06, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
Dopavision gibt Update zur klinischen Studie mit MyopiaX® bekannt; alle Studienzentren aktiv
June 28, 2023 04:00 ET | AKAMPION
- Klinische Erprobung von MyopiaX®, dem ersten Ansatz zur digitalen Behandlung von Kurzsichtigkeit bei Kindern beruhend auf dem Dopamin-Signalweg - Aufnahme von Patienten in Deutschland, Spanien,...
Dopavision proporciona información actualizada sobre los ensayos clínicos y anuncia que todos los centros del ensayo MyopiaX-1 están activos
June 28, 2023 04:00 ET | AKAMPION
- Primer ensayo clínico en humanos de MyopiaX® , el primer enfoque terapéutico para la miopía juvenil dirigido digitalmente a la vía dopaminérgica.- Inscripción en curso en Alemania, España, Países...
Dopavision Provides Clinical Trial Update and Announces All MyopiaX-1 Trial Sites Are Active
June 28, 2023 04:00 ET | AKAMPION
- First-in-human clinical trial of MyopiaX®, the first therapeutic approach in juvenile myopia to target the dopamine pathway digitally- Enrollment ongoing in Germany, Spain, the Netherlands, and the...
revive-therapeutics.png
Revive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
May 30, 2023 07:30 ET | Revive Therapeutics Ltd.
TORONTO, May 30, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...